Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2013, Article ID 905091, 10 pages
Review Article

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

1Medical Oncology Unit, Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro and “Tommaso Campanella” Cancer Center, Campus Salvatore Venuta, Viale Europa, 88100 Catanzaro, Italy
2Institute of Neurological Science (ISN-CNR), UOS of Pharmacology, Roccelletta di Borgia, 88021 Catanzaro, Italy
3Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, 80138 Naples, Italy

Received 31 January 2013; Accepted 5 March 2013

Academic Editor: Giuseppe De Rosa

Copyright © 2013 Iole Cucinotto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.